Working… Menu
Trial record 19 of 1949 for:    "Depressive Disorder" [DISEASE] AND Rating AND Major Depressive Disorder

Efficacy of Light Therapy Device LUMINETTE® in Major Depressive Disorder (LUMIDEP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03685942
Recruitment Status : Recruiting
First Posted : September 26, 2018
Last Update Posted : April 1, 2019
Information provided by (Responsible Party):
Centre Psychothérapique de Nancy

Brief Summary:
This study evaluates the addition of light therapy with LUMINETTE device to usual treatment (antidepressant drug and psychotherapy) in the treatment of Major Depressive Disorder (MDD). Half of the participants will receive active light therapy with LUMINETTE device while the other half will receive placebo light therapy with LUMINETTE placebo device.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Unipolar Depression Device: active light therapy (LUMINETTE®) Device: placebo light therapy Not Applicable

Detailed Description:

Major depressive disorder (MDD) is a world wide spread disorder. According to the World health organization, MDD affects more than 300 million people of all ages in the world. Treatments of MDD include pharmacological treatment and psychotherapy. Pharmacological treatments, mostly serotonin selective reuptake inhibitors, have a delayed onset of action, require long-term treatment and have partial efficacy. In fact, only one third of patients respond to the first antidepressant treatment and two-third after multiple trials. So, there is a need for new treatment strategy.

Light therapy is a well established non pharmacological treatment of seasonal affective disorder, a clinical subtype of affective disorder characterized by recurrent episodes of MDD occurring with a seasonal pattern. Patients are exposed to artificial light for a variable duration and intensity. Although the precise mechanism of bright light therapy remains unknown, it is thought to act through the eyes by activating the suprachiasmatic nucleus, the principal circadian pacemaker.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Light Therapy Device LUMINETTE® in Major Depressive Disorder(LUMIDEP)
Actual Study Start Date : January 16, 2019
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : February 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: active light therapy
Light therapy 1000 lux daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m., during 8 weeks in addition to usual treatment
Device: active light therapy (LUMINETTE®)
light therapy on a portable light visor device

Placebo Comparator: placebo light therapy
People receive usual treatment and use a placebo light therapy device (50 lux) daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m. during 8 weeks.
Device: placebo light therapy
placebo portable light visor device

Primary Outcome Measures :
  1. Montgomery-Åsberg depression rating scale (MADRS) [ Time Frame: week 8 ]
    Rating scale measuring depressive symptoms. Each item is scored from 0 to 3, yielding a total between 0 and 27.

Secondary Outcome Measures :
  1. Pittsburgh Sleep Quality Index (PSQI) [ Time Frame: week 8 ]
    Self reported rating scale measuring quality of sleep

  2. Epworth Sleepiness Scale (ESS) [ Time Frame: week 8 ]
    Self reported rating scale measuring day time sleepiness

  3. Hamilton Anxiety Rating Scale (HAM-A) [ Time Frame: week 8 ]
    Tool measuring the severity of anxiety symptoms.

Other Outcome Measures:
  1. electroretinogramm [ Time Frame: at inclusion, week 4,8 and 12 ]
    test that measure the functional activity of the retina

  2. Hopkins Verbal Learning Test (HVLT) [ Time Frame: week 10 ]
    test of verbal Learning and memory

  3. Montreal Cognitive Assessment (MoCA) [ Time Frame: week 10 ]
    screening assessment for detecting cognitive impairment

  4. Stroop test [ Time Frame: week 10 ]
    test assessing the ability to inhibit cognitive interference

  5. Trail Making Test (TMT) [ Time Frame: week 10 ]
    test evaluating executive functions

  6. Wechsler Adult Intelligence Scale subtest (WAIS) [ Time Frame: week 10 ]
    test evaluating memory

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Major depressive disorder assessed with DSM-IV criteria evaluated with the french version of the Mini International Neuropsychiatric Interview (MINI).

Exclusion Criteria:

  • Others evolutive psychiatric disease (DSM-IV axis I evaluated with the MINI) except anxiety disorders
  • No usual routine treatment of major depressive disorder
  • Previous or actual treatment with light therapy
  • Seasonal major depressive disorder
  • Suicidal risk
  • Active neurologic disease
  • Retinal pathology
  • Pregnant women
  • Breastfeeding women
  • Psychiatric care without consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03685942

Layout table for location contacts
Contact: Eve COSKER +33383925034
Contact: Tatiana DABROWSKI +33383925349

Layout table for location information
Centre Psychothérapique de Nancy Recruiting
Laxou, France, 54200
Contact: Eve COSKER   
Contact: Thomas SCHWITZER   
Sponsors and Collaborators
Centre Psychothérapique de Nancy
Layout table for investigator information
Principal Investigator: Thomas SCHWITZER Centre Psychothérapique de Nancy

Layout table for additonal information
Responsible Party: Centre Psychothérapique de Nancy Identifier: NCT03685942     History of Changes
Other Study ID Numbers: RIPH 2017-02
First Posted: September 26, 2018    Key Record Dates
Last Update Posted: April 1, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Centre Psychothérapique de Nancy:
light therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Pathologic Processes
Behavioral Symptoms
Mood Disorders
Mental Disorders